BMEA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 15.45%, SMA50 10.56%, SMA200 -10.1%). The stock’s 14-day RSI is 61.5 (firm momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.92% below its high and over 66.3% above its low. Average 10-day trading volume of 1.35 million shares is slightly above the 3-month average of 1.12 million, indicating heightened recent market interest.

Biomea Fusion, Inc. has 59.51 million shares outstanding. The public float is 47.42 million shares, elevated short interest at 16.75% of float. This equals 8.05 million shares. The short ratio is 11.73 days. Institutional investors hold 53.46% of the float. Insiders own 9.47%. Stergiopoulos Sotirios holds 4.40 million shares, Chen Bihua has 3.57 million shares and A2A Pharmaceuticals, Inc. has 3.50 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Biomea Fusion, Inc. (NASDAQ:BMEA) closed at $1.22 USD, gaining $0.09 (7.96%) from the previous close of $1.13. The stock is currently mid-range between its 52-week high and low $0.87 and $3.08. With a market capitalization of about $72.59 million, Biomea Fusion, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.21). Key stats such as the average daily volume over the past year has been around 1.09 million shares, trading with heavier-than-usual volume. Headquartered in Redwood City, CA, Biomea Fusion, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael J. Hitchcock, the company employs approximately 79 people and listed since April 16, 2021. Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.

Biomea Fusion, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.04. This means the shares are trading above this model’s fair value.

Biomea Fusion, Inc. generated EPS of -$2.39 over the past year. Five-year average earnings growth is -149.32%. Wall Street analysts project EPS growth of 29.3% annually over the next five years. The latest quarter delivered EPS of -$0.27. The next quarter is forecast at -$0.23. Next year's EPS is expected at -$8.32. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 18 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $3.00. The high target offers 3178.69% upside. The low target suggests 145.9% downside. The mean target is $16.20. This offers 1227.87% upside. Biomea Fusion, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 3.85%. The prior quarter beat by -13.56%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in July 31, 2024.

Biomea Fusion, Inc. trades at a P/E ratio of -0.52, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.19 trading at moderately above to book value. The P/FCF stands at -0.84, also above market averages.

Our AI price prediction model suggests that Biomea Fusion, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -23.77%, with price expected at $0.93 by April 08, 2026, within a range of $0.83 to $1.01 3-Month Outlook: Projected fall of -36.89%, reaching $0.77 by June 22, 2026, with a range of $0.60 to $0.88. 1-Year Outlook: Projected gain of 19.67%, with price at $1.46 by March 25, 2027, within a range of $0.00 to $0.00.

Biomea Fusion, Inc. (NASDAQ:BMEA) shares are up 11.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Biomea Fusion, Inc. trading at a premium to the broader market with a P/E of -0.52. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $36.36, suggesting 2880.33% upside. Our AI forecast model points to short-term weakness (-23.77% over two weeks), a medium-term fall (-36.89% over three months), and a longer-term gain (19.67% over one year), with expected trading ranges indicating moderate volatility.